1. Effectiveness of a multimodal intervention in functionally impaired older people with type 2 diabetes mellitus
- Author
-
Leocadio Rodriguez‐Mañas, Olga Laosa, Bruno Vellas, Giuseppe Paolisso, Eva Topinkova, Juan Oliva‐Moreno, Isabelle Bourdel‐Marchasson, Mikel Izquierdo, Kerry Hood, Andrej Zeyfang, Giovanni Gambassi, Mirko Petrovic, Tim C. Hardman, Mark J. Kelson, Ivan Bautmans, Gabor Abellan, Michelangela Barbieri, Luz M. Peña‐Longobardo, Sophie C. Regueme, Riccardo Calvani, Stefanie De Buyser, Alan J. Sinclair, and on behalf of the European MID‐Frail Consortium
- Subjects
Diabetes ,Older people ,Frailty ,Pre‐frail ,Functional status ,Randomized controlled trial ,Diseases of the musculoskeletal system ,RC925-935 ,Human anatomy ,QM1-695 - Abstract
Abstract Background Type 2 diabetes, a highly prevalent chronic disease, is associated with increasing frailty and functional decline in older people. We aimed to evaluate the effectiveness of a multimodal intervention on functional performance in frail and pre‐frail participants aged ≥70 years with type 2 diabetes mellitus. Methods The MID‐Frail study was a cluster‐randomized multicenter clinical trial conducted in 74 trial sites across seven European countries. The trial recruited 964 participants who were aged >70 years [mean age in intervention group, 78.4 (SD 5.6) years, 49.2% male and 77.6 (SD 5.29) years, 52.4% male in usual care group], with type diabetes mellitus and determined to be frail or pre‐frail using Fried's frailty phenotype. Participants were allocated by trial site to follow either usual care (UCG) or intervention procedures (IG). Intervention group participants received a multimodal intervention composed of (i) an individualized and progressive resistance exercise programme for 16 weeks; (ii) a structured diabetes and nutritional educational programme over seven sessions; and (iii) Investigator‐linked training to ensure optimal diabetes care. Short Physical Performance Battery (SPPB) scores were used to assess change in functional performance at 12 months between the groups. An analysis of the cost‐effectiveness of the intervention was undertaken using the incremental cost‐effectiveness ratio (ICER). Secondary outcomes included mortality, hospitalization, institutionalization, quality of life, burden on caregivers, the frequency and severity of hypoglycaemia episodes, and the cost‐effectiveness of the intervention. Results After 12 months, IG participants had mean SPPB scores 0.85 points higher than those in the UCG (95% CI, 0.44 to 1.26, P
- Published
- 2019
- Full Text
- View/download PDF